Orforglipron
ATTAIN-1
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 3127
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r | n/r |
| 6 mg Orforglipron | n/r | n/r | n/r | n/r | n/r |
| 12 mg Orforglipron | n/r | n/r | n/r | n/r | n/r |
| 36 mg Orforglipron | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.